Stocks
Cadrenal Therapeutics, Inc.CVKD
NASDAQHealthcareBiotechnology$0.95
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing a novel anticoagulant, caldolor, for the prevention of thromboembolic events in patients with renal impairment. Its lead candidate, CVK-101, is in Phase 3 trials, and the company is focused on addressing an unmet need in a niche cardiovascular niche. Investors track CVKD for its high-risk, high-reward clinical pipeline and potential regulatory milestones.
52W Range: $0.82-$14.21
Congressional Interest in Cadrenal Therapeutics, Inc. (CVKD)
No congressional trades have been disclosed for Cadrenal Therapeutics, Inc. (CVKD) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading CVKD?
No congressional trades found for this stock.